- 24/7 Wall St.•42 minutes ago
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
- The Wall Street Journal•2 hours ago
Among the companies with shares expected to trade actively in Monday's session are Chemtura, Deutsche Bank AG, and Array BioPharma.
- PR Newswire•4 hours agoArray BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint
BOULDER, Colo., Sept. 26, 2016 /PRNewswire/ -- Array BioPharma (ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162 (binimetinib), a MEK inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The study met its primary endpoint, significantly improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor, alone.
Array BioPharma Inc. (ARRY)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||5.81 x 200|
|Ask||5.82 x 1300|
|Day's Range||4.59 - 5.88|
|52wk Range||2.38 - 5.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.63|
|Avg Vol (3m)||1,958,150|
|Dividend & Yield||N/A (N/A)|